The 3CTN governance structure provides scientific and operational oversight to ensure the network operates effectively and efficiently with transparent decision-making processes.
The governance structure is comprised of the following committees:
- Steering Committee;
- Executive Committee;
- Strategic Council;
- Scientific Advisory Board.
Each committee is representative of stakeholders across Canada and their respective interests and priorities. In Phase I, the committees are structured in a way that will facilitate the development of the 3CTN business plan. In Phase II, committee membership may be modified as required to govern the network.
Chaired by Dr. Ian Tannock, the Steering Committee is responsible for the operational management of the Network.
Steering Committee responsibilities include:
- The oversight of processes for implementing 3CTN scientific and operational objectives;
- Ensuring 3CTN deliverables for cancer clinical trials;
- Promoting the necessary collaborations and communication;
- Reviewing finances, milestones and deliverables against projections;
- Approving the annual budget for the network;
- Reporting to funders.
The Executive Committee will act on behalf of the Steering Committee (SC) on urgent matters arising between regular SC meetings in cases where it is not possible to convene a meeting of the SC or have quorum, and will act in other matters as delegated by the Steering Committee.
The Strategic Council (STC) is a senior advisory body for Network sustainability and stakeholder engagement. It is comprised of high level members formerly or currently in government, industry, scientific community and patient advocates to advise 3CTN on approaches to government and other sources/ opportunities of funding. The members will advocate on 3CTN's behalf publicly and raise the Network profile accross stakeholder groups.
Scientific Advisory Board
The Scientific Advisory Board is responsible for advising the network on strategic priorities, policies and trends.
Scientific Advisory Board responsibilities include:
- Making recommendations for the network’s strategic priorities for trials and activities;
- Evaluating the progress of the network at 18 and 36 months;
- Advising on policies and trends in health care, science, and technology related to trials.